Loading…
← CockpitCompetitor Analysis › RGC Regencell Bioscience Holdings Ltd.Open in the cockpit ↗

Regencell Bioscience Holdings Ltd.RGCCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Hong Kong company developing traditional-Chinese-medicine formulations for ADHD and autism spectrum disorder.

Momentum laggard 6
Mkt cap
$2.33B
US dollars, full cap
Free float
11%
of shares outstanding
$/day
$1.22M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 13.1%
Hurdle
n/a
no reverse DCF
Close · USD$4.69
1D+3.1%
1W-13.3%
1M-55.1%
3M-13.8%
6M-82.9%
YTD-77.7%
1Y-63.7%
ATR %15.0%
Beta1.23
52w lowhigh93.2% off high

What Regencell Bioscience does

Hong Kong company developing traditional-Chinese-medicine formulations for ADHD and autism spectrum disorder.

Has no product to sell, so there is no product revenue; it is funded by cash raised from selling shares and spends on research and trials. Its treatments are traditional herbal formulas not yet approved by Western drug regulators, so value rests on future data rather than sales. A small share of the stock trades freely.

Products and services

  • TCM herbal formulations (ADHD/ASD)

Where it sits in the supply chain

  • Traditional Chinese medicine (TCM)
  • Herbal formulation R&D
  • Neurodevelopmental-disorder treatments

What could go right

  • Positive clinical/validation data
  • Speculative trading interest (thin float)

What could go wrong

  • No proven efficacy under Western trial standards
  • Extremely thin float/high volatility

Moat: none. Pre-revenue, unproven TCM approach with no Western regulatory approval or peer-reviewed efficacy data.

Headquarters: Hong Kong · Founded: 2014 · Employees: 10

Named competitors

Regencell Bioscience at a glance

Size Regencell Bioscience (RGC) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.33B, the 1689th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.69 on 18 Nov 2026.

Performance Over six months the shares fell 82.9%, against -9.0% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 92RGC 17
Six months, rebased to 100: Regencell Bioscience against the median of its 20 peers (local-currency closes).

Regencell Bioscience financials

Reported figures in USD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$404,543-$404,543-$392,743-$745,588-$769,687
EBITDA-$11.3M-$11.3M-$3.38M-$3.99M-$5.50M
Net income-$11.7M-$11.7M-$3.58M-$4.30M-$5.87M
Free cash flow-$7.70M-$7.70M-$3.27M-$4.01M-$4.99M
Capital expenditure$0$0$152,689$5,376$27,392
Total debtn/a$295,811$544,415$85,741$463,669

Quarterly statements and history in the cockpit →

Regencell Bioscience competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%301080PRGO000250NAMS001321623696PBH603858APLLTD600867600267IDYA214450H02688428600285RGC6-month return →1-month return →
Up and to the right = strong over both horizons. Regencell Bioscience is the large dot.

Regencell Bioscience competitors and peer comparison

Head to head with its named competitors (RGC vs SUPN vs JAZZ)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Regencell Bioscience RGC$2.33B-83%n/an/an/an/a
Supernus Pharmaceuticals SUPN$6.02B-41%+16%45%4.5×6.2%
Jazz Pharmaceuticals Public JAZZ$15.9B+4%+13%25%4.0×-2.8%

How Regencell Bioscience compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Regencell Bioscience against its 20 peers (data as of 18 Nov 2026)
MeasureRGCPeer medianRank in peer set
1-month return-55.1%-4.4%lowest of 21
6-month return-82.9%-9.0%lowest of 21
Distance from 52-week high-93.2%-30.8%lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Regencell Bioscience RGCUnited States$2.33B-83%n/an/an/an/an/a
Acrobiosystems 301080.SZChina$2.31B+65%+29%17%14.0×41.3%+27.7%
Perrigo PRGOUnited States$2.35B+52%-4%5%1.3×14.1%+0.8%
Sam Chun Dang Pharm 000250.KSSouth Korea$2.36B-66%+23%7%11.8×n/an/a
NewAmsterdam Pharma NAMSUnited States$2.37B-45%-26%-900%67.0×n/an/a
HUTCHMED (China) 0013.HKHong Kong$2.38B+14%-9%-6%2.0×47.0%+19.3%
Keymed Biosciences 2162.HKHong Kong$2.39B+7%0%-73%16.8×n/an/a
InSilico Medicine Cayman TopCo 3696.HKHong Kong$2.40B-33%+153%-7%13.6×37.9%+22.9%
Prestige Consumer Healthcare PBHUnited States$2.40B+7%+5%25%3.8×2.3%+2.9%
Shandong Buchang Pharmaceuticals 603858.SSChina$2.25B-7%+4%10%1.5×-2.5%-5.8%
Alembic Pharmaceuticals APLLTD.NSIndia$2.20B+39%+20%12%2.6×26.7%+6.5%
Tonghua Dongbao Pharmaceutical 600867.SSChina$2.19B-12%+18%n/a4.2×0.9%+0.3%
Zhejiang Hisun Pharmaceutical 600267.SSChina$2.19B+14%-7%15%1.7×-9.7%-1.5%
Almirall ALM.MCSpain$2.46B-13%+24%8%1.9×6.1%+6.5%
Yili Chuanning Biotechnology 301301.SZChina$2.49B-24%-14%16%4.2×3.4%+4.8%
IDEAYA Biosciences IDYAUnited States$2.56B-11%-83%-1,267%48.0×n/an/a
PharmaResearch 214450.KSSouth Korea$2.10B-24%+29%37%4.0×-11.0%+37.6%
Haw Par H02.SISingapore$2.08B-25%-13%30%8.4×3.2%+15.7%
Kangmei Pharmaceutical 600518.SSChina$2.61B-21%-6%-7%3.3×n/an/a
InnoCare Pharma 688428.SSChina$2.07B-7%+135%35%2.8×-10.9%+344.2%
Henan Lingrui Pharmaceutial 600285.SSChina$2.04B+9%+5%22%3.3×-4.7%+10.6%

Questions

Who are Regencell Bioscience's main competitors?
Named competitors: Supernus Pharmaceuticals (SUPN), Jazz Pharmaceuticals (JAZZ). The cockpit's measured peer set (industry) also includes Acrobiosystems (301080.SZ), Perrigo (PRGO), Sam Chun Dang Pharm (000250.KS), NewAmsterdam Pharma (NAMS), HUTCHMED (China) (0013.HK), Keymed Biosciences (2162.HK).
How has Regencell Bioscience stock performed?
Over six months to 18 Nov 2026 the shares returned -82.9% against -9.0% for the median peer; over one year -63.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.